

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA524 [review of TA446], TA478)**

**NICE GUIDANCE ISSUED APRIL 2018, OCTOBER 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

## **Final Appraisal Recommendation**

**Advice No: 1215 – May 2015**

## **Brentuximab vedotin (Adcetris<sup>®</sup>▼)**

**50 mg powder for concentrate for solution for infusion**

**Submission by Takeda UK Limited**

### **Recommendation of AWMSG**

**Brentuximab vedotin (Adcetris<sup>®</sup>▼) is recommended for restricted use within NHS Wales for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.**

**Brentuximab vedotin (Adcetris<sup>®</sup>▼) is not recommended for use within NHS Wales for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).**

#### **Additional note(s):**

- AWMSG considered that Brentuximab vedotin (Adcetris<sup>®</sup>▼) satisfied the AWMSG criteria for ultra orphan drug status.
- The applicant company did not supply clinical or cost effectiveness data for brentuximab vedotin in patients with relapsed or refractory sALCL.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1255), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1215:  
brentuximab vedotin (Adcetris<sup>®</sup>) 50 mg powder for concentrate for solution for infusion. May 2015.